Oruka Therapeutics, INC Form 4 insider transactions

Arjun Agarwal, SVP of Finance at Oruka Therapeutics, Inc., reported the acquisition of 17,500 common shares and 70,000 employee stock options through grants.

Oruka Therapeutics, Inc. CEO Lawrence Otto Klein was granted 76,700 shares of common stock and options to purchase 306,700 shares.

Oruka Therapeutics General Counsel Paul T. Quinlan received a grant of 32,500 common shares and 130,000 employee stock options.

Oruka Therapeutics Director Carl Dambkowski reported the acquisition of 116,483 shares of common stock through a pro-rata distribution from an LLC.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of the acquired common stock under a pre-arranged trading plan.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, reported exercising warrants and selling a portion of her common stock holdings.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of her common stock holdings under a pre-arranged trading plan.

Oruka Therapeutics, Inc. director Christopher Nathan received a grant of 35,000 stock options with an exercise price of $30.21, vesting monthly over three years.

Fairmount Funds Management and its affiliates acquired 333,340 shares of Oruka Therapeutics common stock in a private placement for $15 per share.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler was granted 25,000 employee stock options with an exercise price of $11.80, vesting over four years.

Oruka Therapeutics, Inc. has granted 17,500 stock options to entities and individuals associated with Fairmount Funds Management LLC, including directors Peter Harwin and Tomas Kiselak, aligning their interests with the company's long-term performance.

Oruka Therapeutics, Inc. Director Samarth Kulkarni was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Carl Dambkowski was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Cameron Turtle has acquired 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Kristine M. Ball was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in Oruka Therapeutics, Inc. through a series of open market purchases.

Arjun Agarwal, SVP of Finance at Oruka Therapeutics, reported the acquisition of 120,000 stock options on January 22, 2025.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, was granted 162,500 stock options on January 22, 2025, which vest monthly starting January 1, 2025.

Oruka Therapeutics' General Counsel, Paul T. Quinlan, has acquired 162,500 stock options, vesting monthly from January 1, 2025.

Oruka Therapeutics' CEO, Lawrence Otto Klein, was granted 230,000 stock options on January 22, 2025, which vest monthly over four years.

Fairmount Funds Management converted 160 shares of Series A Preferred Stock into 160,000 shares of Oruka Therapeutics common stock following shareholder approval.

Fairmount Funds Management and related entities report acquisition of common stock and convertible preferred stock in Oruka Therapeutics through a private placement.

Jacob Ma-Weaver, formerly a director of ARCA biopharma, Inc., reports changes in beneficial ownership following the company's business combination on August 29, 2024, including the cancellation of incentive options and assignment of proceeds.

ARCA biopharma updates the special cash dividend amount to $1.613 per share in connection with its merger with Oruka Therapeutics, payable on August 28, 2024.

Janus Henderson Group PLC reports increased beneficial ownership in ARCA biopharma, Inc. through fund transactions.

ARCA biopharma declares a special cash dividend estimated at $1.59 per share in connection with its proposed merger with Oruka Therapeutics, pending stockholder approval.

ARCA Biopharma divests its legacy Gencaro and rNAPc2 assets to Genvara Biopharma for $300,000 as it progresses with its merger with Oruka Therapeutics.

ARCA Biopharma is set to merge with Oruka Therapeutics in a reverse-triangle merger, accompanied by a $275 million private investment in Oruka.

ARCA biopharma reported its second quarter 2024 financial results, highlighting cash reserves and ongoing strategic review, including a proposed merger with Oruka Therapeutics.

Janus Henderson Group PLC reports acquiring additional shares of ARCA biopharma, Inc., increasing its indirect beneficial ownership.